Abstracts tagged "Behavioral strategies and rheumatoid arthritis (RA)"

Abstract Number: 2257 • 2019 ACR/ARP Annual Meeting
Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial
Adam Taylor¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: The treat to target (T2T) treatment strategy is associated with better clinical outcomes in patients with rheumatoid arthritis (RA). We have previously found that…
Abstract Number: 1924 • 2018 ACR/ARHP Annual Meeting
Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
Maria I. Danila¹, Lang Chen¹, Justin K Owensby¹, Ronan O'Beirne¹, Joshua A. Melnick¹, Eric M. Ruderman², Leslie R. Harrold³ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Controlling disease activity in RA using a treat-to-target (T2T) strategy can optimize clinical and patient-important outcomes. Yet, many patients are not familiar with T2T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].